Analysts Set Shattuck Labs, Inc. (NASDAQ:STTK) Target Price at $10.00

Shares of Shattuck Labs, Inc. (NASDAQ:STTK) have been assigned a consensus recommendation of “Moderate Buy” from the eight research firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $10.00.

A number of equities analysts recently issued reports on STTK shares. Weiss Ratings restated a “sell (d-)” rating on shares of Shattuck Labs in a report on Thursday, January 22nd. Wedbush increased their target price on Shattuck Labs from $4.00 to $8.00 and gave the stock an “outperform” rating in a research note on Friday, March 6th. Citigroup boosted their target price on shares of Shattuck Labs from $2.00 to $4.00 and gave the company a “neutral” rating in a research note on Tuesday, January 6th. TD Cowen restated a “buy” rating on shares of Shattuck Labs in a report on Friday, March 6th. Finally, HC Wainwright raised shares of Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 price target on the stock in a research note on Monday, December 1st.

Shattuck Labs Price Performance

Shattuck Labs stock opened at $5.88 on Monday. Shattuck Labs has a 1-year low of $0.69 and a 1-year high of $6.25. The firm has a market capitalization of $420.80 million, a P/E ratio of -7.64 and a beta of 1.55. The company’s 50-day moving average is $4.31 and its 200 day moving average is $2.95.

Shattuck Labs (NASDAQ:STTK) last announced its earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). The business had revenue of ($1.00) million for the quarter, compared to analysts’ expectations of $0.17 million. Research analysts anticipate that Shattuck Labs will post -1.48 earnings per share for the current fiscal year.

Institutional Trading of Shattuck Labs

Institutional investors and hedge funds have recently modified their holdings of the stock. Turtle Creek Wealth Advisors LLC purchased a new stake in shares of Shattuck Labs in the third quarter valued at approximately $29,000. Virtu Financial LLC purchased a new position in Shattuck Labs during the 3rd quarter worth $38,000. Squarepoint Ops LLC bought a new stake in Shattuck Labs during the 3rd quarter valued at $46,000. Mallini Complete Financial Planning LLC bought a new stake in Shattuck Labs during the 4th quarter valued at $83,000. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of Shattuck Labs in the 4th quarter worth $85,000. Institutional investors own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.